HIT · Health In Tech, Inc.

Health In Tech’s Q1 2026 results reflect deliberate strategic investment ahead of anticipated revenue inflection: revenue grew 9.4% YoY to $8.8 million, driven by expanded distribution (896 partners, +29.5% YoY) and platform placed plan value of $82.0 million, yet profitability reversed with a $1.6 million net loss and Adjusted EBITDA of $(1.3) million — a $2.5 million swing from Q1 2025’s $1.2 million — explicitly attributed to elevated sales and marketing spend for long-term growth. The company’s $22.9 million in contracted revenue for the remainder of 2026 underpins its reiterated $45–$50 million full-year guidance, representing 35–50% YoY growth, and signals strong visibility into near-term revenue recognition given its ratably recognized, 12-month policy terms. A March 2026 PIPE financing generated ~$7 million in gross proceeds (net $6.4 million), enabling targeted investments in sales capacity, new marketplace offerings—including over 100 pre-configured stop-loss plans and a three-year rate stabilization program—and data analytics infrastructure. Management emphasized the competitive advantage of its AI-driven platform’s rapid deployment cycle (one to two quarters versus one to two years industry-wide), positioning these near-term investments to accelerate revenue capture in H2 2026 and beyond. While working capital improved to $15.0 million and cash rose to $10.3 million, operating cash flow used $3.3 million, underscoring the intensity of current growth spending; however, the combination of high contracted revenue, robust partner growth, and scalable technology architecture supports the credibility of the full-year outlook despite near-term margin pressure.